Vaccine development

NTI utilizes a novel vaccine production system that results in superior vaccine formulations for infectious disease as compared to conventional methods.
vaccines:

1. replace live vaccines with an inactivated counterpart, thereby greatly reducing the chance for serious adverse events in vaccinated individuals.
2. preserve important immunologic epitopes including neutralizing epitopes and T cell epitopes.
3. are amenable to stable, preservative-free formulations.

The properties inherent to our vaccine development platform make them ideal candidates for use in developing countries in which an effective cold-chain is often difficult to establish. In addition, because vaccines are inactivated, they are suitable for immunizing vulnerable populations such as the very young, the elderly and the immunocompromised - individuals in whom live virus vaccines may be contraindicated. We are interested in applying the platform to the development of effective and safe vaccines against emerging infectious diseases -- especially serious diseases that pose a threat in endemic countries as well as to the US military and international travelers.